Agios Pharmaceuticals (AGIO) Capital Expenditures (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Capital Expenditures data on file, last reported at $1.2 million in Q2 2026.

• Quarterly Capital Expenditures rose 38.51% year-over-year to $1.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.7 million (up 53.82% YoY) and the FY2025 annual result came in at $4.3 million, up 156.14% from the prior year.
• Capital Expenditures advanced to $1.2 million in Q2 2026, from $769000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $2.8 million in Q1 2022 to a low of -$3000.0 in Q2 2023.
• A 5-year average of $770111.1 and a median of $592500.0 in 2024 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures plunged 100.16% — and 2024, when it surged 5366.67%.
• Tracing AGIO's Capital Expenditures over 5 years: stood at $113000.0 in 2022, then jumped by 107.08% to $234000.0 in 2023, then jumped by 313.25% to $967000.0 in 2024, then climbed by 15.82% to $1.1 million in 2025, then grew by 8.21% to $1.2 million in 2026.
• The last three Capital Expenditures figures came in at $1.2 million (Q2 2026), $769000.0 (Q1 2026), and $1.1 million (Q4 2025), per Business Quant data.